Laboratorios Farmaceúticos Rovi SA (LABFF)
67.17
0.00 (0.00%)
USD |
OTCM |
Aug 26, 16:00
Laboratorios Farmaceúticos Rovi Shareholders Equity (Quarterly) : 801.02M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 801.02M |
| March 31, 2026 | 776.47M |
| December 31, 2025 | 780.32M |
| September 30, 2025 | 730.54M |
| June 30, 2025 | 661.62M |
| March 31, 2025 | 637.18M |
| December 31, 2024 | 592.34M |
| September 30, 2024 | 612.35M |
| June 30, 2024 | 510.25M |
| March 31, 2024 | 561.25M |
| December 31, 2023 | 595.83M |
| September 30, 2023 | 583.90M |
| June 30, 2023 | 563.66M |
| March 31, 2023 | 616.30M |
| December 31, 2022 | 554.98M |
| September 30, 2022 | 432.93M |
| June 30, 2022 | 417.16M |
| March 31, 2022 | 473.49M |
| December 31, 2021 | 535.59M |
| September 30, 2021 | 525.04M |
| June 30, 2021 | 478.94M |
| March 31, 2021 | 467.00M |
| December 31, 2020 | 457.24M |
| September 30, 2020 | 433.24M |
| June 30, 2020 | 395.62M |
| Date | Value |
|---|---|
| March 31, 2020 | 369.02M |
| December 31, 2019 | 361.88M |
| September 30, 2019 | 342.11M |
| June 30, 2019 | 340.85M |
| March 31, 2019 | 330.63M |
| December 31, 2018 | 328.62M |
| September 30, 2018 | 233.58M |
| June 30, 2018 | 225.47M |
| March 31, 2018 | 244.28M |
| December 31, 2017 | 230.18M |
| September 30, 2017 | 226.32M |
| June 30, 2017 | 216.84M |
| March 31, 2017 | 203.24M |
| December 31, 2016 | 193.45M |
| September 30, 2016 | 201.17M |
| June 30, 2016 | 194.97M |
| March 31, 2016 | 198.26M |
| December 31, 2015 | 179.01M |
| September 30, 2015 | 181.08M |
| June 30, 2015 | 177.46M |
| March 31, 2015 | 177.36M |
| December 31, 2014 | 191.76M |
| September 30, 2014 | 195.16M |
| June 30, 2014 | 206.96M |
| March 31, 2014 | 206.69M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Almirall SA | -- |
| AstraZeneca PLC | 47.33B |
| ANI Pharmaceuticals, Inc. | 597.21M |
| Corcept Therapeutics, Inc. | 705.78M |
| Veru, Inc. | 28.38M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.289B |
| Total Liabilities (Quarterly) | 468.72M |
| Debt to Equity Ratio | 0.1537 |
| Current Ratio | 2.054 |
| Net Debt Paydown Yield | -0.04% |